BC Week In Review | Apr 15, 2013
Company News

Symyx Technologies, Hoechst AG deal

The companies began a long-term research collaboration in which Symyx will apply its combinatorial chemistry technology toward material science applications such as chemical catalysts. Hoechst will spend $10 million on research at Symyx over the...
BioCentury | Apr 11, 2005
Strategy

Combinature takes the natural path

After finding it hard to generate deals for its drug discovery platform - and harder still to fund its approach in today’s product-oriented environment - natural compound play Combinature Biopharm AG is moving into the product space...
BioCentury | May 26, 2003
Finance

Vaccinating investors

One of the quietly expressed fears in Europe is that as biotech companies become successful, they will be picked off by their more mature U.S. cousins. That is precisely what happened last week, as one...
BioCentury | Mar 24, 2003
Strategy

Chiron's missing link

Stepping aside almost five years to the day after joining Chiron Corp. as president and CEO, Sean Lance is likely to be remembered as a transitional CEO who streamlined the company's business units and pared...
BioCentury | May 13, 2002
Strategy

Pharma's future

It's hardly news that the pharma group is in a near-term funk. The clear and present danger from generics - which will be accelerating, not dissipating - has nearly rendered the big pharma group dead money for...
BioCentury | Mar 13, 2000
Politics, Policy & Law

The course of least resistance

OXFORD - Europe's virtual moratorium on commercial GM crop planting was maintained last week when the regulatory committee of member states ducked a decision on three applications to place modified products on the European market. The...
BC Week In Review | Jan 31, 2000
Company News

Hemispherx, Aventis deal

HEB received a grant from Rhone-Poulenc SA, which merged with Hoechst AG to form AVE, to develop HEB's nucleic acid therapeutics to treat chronic fatigue syndrome (CFS) and other indications. HEB said it may grant...
BC Week In Review | Jan 4, 2000
Company News

Hoechst AG, Rhone-Poulenc SA deal

The companies completed in December their merger to form Aventis S.A. (AVE, Strasbourg, France) (see BioCentury, Dec. 7, 1998). ( Taxotere approved, B7) Hoechst AG , Frankfurt, Germany   Rhone-Poulenc SA , Paris, France   Business: Pharmaceuticals  ...
BC Week In Review | Dec 13, 1999
Company News

Hoechst AG, Rhone-Poulenc SA deal

The U.S. Federal Trade Commission approved the merger of the companies to form Aventis SA after the companies agreed to divest Rhone-Poulenc. s Rhodia specialty chemical unit and Rhone-Poulenc. s rights to its Revasc direct...
BioCentury | Dec 13, 1999
Product Development

Flamel adds clout to its human touch

Any new insulin product entering the market will inevitably face severe competition from half a dozen approved insulin products and more on the way. As a newcomer to the field, Flamel Technologies S.A. has an...
Items per page:
1 - 10 of 43
BC Week In Review | Apr 15, 2013
Company News

Symyx Technologies, Hoechst AG deal

The companies began a long-term research collaboration in which Symyx will apply its combinatorial chemistry technology toward material science applications such as chemical catalysts. Hoechst will spend $10 million on research at Symyx over the...
BioCentury | Apr 11, 2005
Strategy

Combinature takes the natural path

After finding it hard to generate deals for its drug discovery platform - and harder still to fund its approach in today’s product-oriented environment - natural compound play Combinature Biopharm AG is moving into the product space...
BioCentury | May 26, 2003
Finance

Vaccinating investors

One of the quietly expressed fears in Europe is that as biotech companies become successful, they will be picked off by their more mature U.S. cousins. That is precisely what happened last week, as one...
BioCentury | Mar 24, 2003
Strategy

Chiron's missing link

Stepping aside almost five years to the day after joining Chiron Corp. as president and CEO, Sean Lance is likely to be remembered as a transitional CEO who streamlined the company's business units and pared...
BioCentury | May 13, 2002
Strategy

Pharma's future

It's hardly news that the pharma group is in a near-term funk. The clear and present danger from generics - which will be accelerating, not dissipating - has nearly rendered the big pharma group dead money for...
BioCentury | Mar 13, 2000
Politics, Policy & Law

The course of least resistance

OXFORD - Europe's virtual moratorium on commercial GM crop planting was maintained last week when the regulatory committee of member states ducked a decision on three applications to place modified products on the European market. The...
BC Week In Review | Jan 31, 2000
Company News

Hemispherx, Aventis deal

HEB received a grant from Rhone-Poulenc SA, which merged with Hoechst AG to form AVE, to develop HEB's nucleic acid therapeutics to treat chronic fatigue syndrome (CFS) and other indications. HEB said it may grant...
BC Week In Review | Jan 4, 2000
Company News

Hoechst AG, Rhone-Poulenc SA deal

The companies completed in December their merger to form Aventis S.A. (AVE, Strasbourg, France) (see BioCentury, Dec. 7, 1998). ( Taxotere approved, B7) Hoechst AG , Frankfurt, Germany   Rhone-Poulenc SA , Paris, France   Business: Pharmaceuticals  ...
BC Week In Review | Dec 13, 1999
Company News

Hoechst AG, Rhone-Poulenc SA deal

The U.S. Federal Trade Commission approved the merger of the companies to form Aventis SA after the companies agreed to divest Rhone-Poulenc. s Rhodia specialty chemical unit and Rhone-Poulenc. s rights to its Revasc direct...
BioCentury | Dec 13, 1999
Product Development

Flamel adds clout to its human touch

Any new insulin product entering the market will inevitably face severe competition from half a dozen approved insulin products and more on the way. As a newcomer to the field, Flamel Technologies S.A. has an...
Items per page:
1 - 10 of 43